News | February 18, 2008

Statin Pretreatment Improves Myocardial Perfusion Post Angioplasty

February 19, 2008 - Among patients with acute myocardial infarction (AMI), prior statin therapy is associated with better perfusion after primary angioplasty of the infarct-related artery, according to a report in the January 15 issue of the American Journal of Cardiology.

Recent studies have demonstrated the benefits of statin therapy on endothelial function, inflammation, and platelet activation in patients with stable atherosclerosis, the authors point out.

Rainer Hoffmann, M.D., and colleagues from University Hospital RWTH, Aachen, Germany, sought to determine whether pretreatment with statins decreased inflammatory activity and improved myocardial perfusion in 253 consecutive patients undergoing primary angioplasty within 12 hours of AMI.

The 86 patients who had been taking a statin for at least a week before the MI were more likely to show normal myocardial perfusion and less likely to show impaired perfusion after angioplasty than were the 167 control patients, the investigators report.

Statin-treated patients had a lower frequency of increased C-reactive protein level on admission compared with control patients.

Independent predictors of normal myocardial perfusion in a multivariate regression analysis included age of 70 years or less, non-increased C-reactive protein, and statin pretreatment.

"This was not a prospective randomized study," the researchers noted. "However, unless a large population-based study is performed, it will be impossible to define in a randomized fashion the impact of statin pretreatment for patients developing AMI because of the relatively low incidence of AMI in a healthy population."

For more information:

Related Content

Gore Molding & Occlusion Balloon for Endovascular Aortic Repair Receives FDA Approval
Technology | Balloon Catheter | August 23, 2018
W. L. Gore & Associates Inc. (Gore) announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Gore...
Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init